Atrial fibrillation, often abbreviated as AFib or AF, is a common arrhythmia (heart rhythm disorder) that affects millions of people worldwide. This condition can lead to blood clots, an increased risk of stroke, heart failure and other cardiovascular-related problems. In the United States, this condition is alone is responsible for 450,000 hospitalizations and 158,000 deaths per year, primarily due to the elevated risk of ischemic stroke.
Oral anticoagulants have been instrumental in reducing the risk of strokes in patients with AFib. However, some individuals cannot take these medications due to a higher risk of internal bleeding, which may result from factors like high blood pressure, kidney or liver disease, or excessive alcohol consumption. For such patients, the Watchman device is a valuable, permanent alternative.
To understand how exactly the Watchman device functions, it is essential to first comprehend the science behind atrial fibrillation. AFib is characterized by irregular and rapid signals in the atria, the upper chambers of the heart, which cause the atria to contract in a chaotic and irregular manner. This situation can lead to blood pooling in the atria because the blood is not pumped efficiently from chamber to chamber. Blood pooling can cause blood clots to form inside the heart, with the left atrium appendage (LAA) being the most common site for clot development.
Cardiovascular System
Image Source: SDI Productions
Left atrial appendage closure (LAAC) is a surgical procedure that involves the use of a device, like Watchman device, to seal off the LAA. The Watchman device is a small device about the size of a quarter that specifically blocks the LAA’s opening, preventing the formation of blood clots and therefore, eliminating the need to take anticoagulant medication.
Two months ago, Boston Scientific announced the FDA approval for the latest-generation WATCHMAN FLX Pro Left Atrial Appendage Closure device. The previous model experienced rare complications where blood clots form on the surface of the device and induced additional thromboembolism (blocking of blood vessels). Now the upgraded device features a polymer coating designed to reduce device-related thrombus and enhance adhesion to the heart. Furthermore, the new model consists of visualization markers to improve the precision of device placement and ensure an optimal seal around the LAA.
This news represents a notable step forward in improving the safety and effectiveness of left atrial appendage closure procedure and overall cardiac care. With these advancements, we move closer to a future where individuals with atrial fibrillation can lead healthier, fuller lives without the need of blood-thinner medication.
Featured Image Source: sudok1
